Results 51 to 60 of about 117,776 (72)

Corrigendum: UImer JM, Janšta P, Azar D, Krogmann L (2023) At the dawn of megadiversity – Protoitidae, a new family of Chalcidoidea (Hymenoptera) from Lower Cretaceous Lebanese amber. Journal of Hymenoptera Research 96: 879–924. doi: 10.3897/jhr.96.105494 [PDF]

Journal of Hymenoptera Research
Jonah M. Ulmer, Petr Janšta, Dany Azar, Lars Krogmann   +3 more
doaj   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022
Xueyan Zhang, Yuqing Lou, Tianqing Chu   +2 more
exaly  

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects

Frontiers in Pharmacology, 2022
Guoping Yang, Heng Yang, Yuxia Xiang
exaly  

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of Hematology and Oncology, 2023
Yuanyuan Zhao, Shenhong Qu, Yuxiang Ma   +2 more
exaly  

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Ophthalmology and Therapy, 2023
Mengli Zhu, Song Yanping, Yuan Huiping   +2 more
exaly  

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

Frontiers in Immunology, 2023
Yun Fan, Zhiyu Huang, Meng Xiangrui
exaly  

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Acta Pharmacologica Sinica, 2022
Bo Ban, Zhenlin Zhang, Zhang Qiu
exaly  

Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial

Reproductive BioMedicine Online, 2023
exaly  

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

Cancer Chemotherapy and Pharmacology, 2020
Guoping Yang, Can Guo
exaly